Health News: Promising Pill Treatment for Snoring and OSA Symptoms
Promising Results in Snoring Treatment
The first pill for snoring may soon be available, following health news from a recent study that demonstrated significant benefits for obstructive sleep apnoea (OSA) sufferers. A clinical trial presented at the European Respiratory Society showed that a daily dose of sulthiame could reduce symptoms by up to half.
Study Details
This study involved 298 participants in a double-blind, randomised, placebo-controlled trial across 28 centres in Europe. Patients were monitored for breathing patterns, oxygen levels, and other vital signs over 12 weeks. Participants took varying doses of sulthiame or a placebo.
- Patients reported fewer pauses in breathing and increased oxygen saturation during sleep.
- Reduction in respiratory pauses was significant, with the highest dose achieving nearly 40% less AHI3a.
Further Research Needed
Despite encouraging results, further studies are required to evaluate the long-term impacts of sulthiame on OSA and explore potential benefits for managing cardiovascular risks.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.